1. Fernandes Silva L, Ravi R, Vangipurapu J, Laakso M. Metabolite signature of simvastatin treatment involves multiple metabolic pathways. Metabolites, 2022. 12:753. doi: 10.3390/metabo12080753.
2. Brinton EA. Statin-Related New-Onset Diabetes Appears Driven by Increased Insulin Resistance: Are There Clinical Implications? Arterioscler Thromb Vasc Biol. 2021; 41: 2798–2801. DOI: 10.1161/ ATVBAHA.121.316893
3. Laakso M, Fernandes Silva L. Statins and risk of type 2 diabetes: mechanism and clinical implications.Front. Endocrinol. 2023. 14:1239335.
doi: 10.3389/fendo.2023.1239335
4. Sattar N. Statins and diabetes: What are the connections? Best Practice & Research Clinical Endocrinology & Metabolism, 2023. 37:101749. https://doi.org/10.1016/j.beem.2023.101749
5. Freeman DJ, Norrie J, Sattar N, Neely RD, Cobbe SM, Ford I, et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation, 2001. 103:357–62. doi: 10.1161/01.CIR.103.3.357
6. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet, 2002. 360(9346):1623–30. doi: 10.1016/S0140-6736(02)11600-X
7. Sabatine MS, Wiviott SD, Morrow DA, McCabe CH, Canon CP. High dose atorvastatin associated with worse glycemic control: a PROVE-IT TIMI 22 substudy. Circulation, 2004. 110:Suppl:S834. doi: 10.7860/JCDR/2017/23741.9427
8. de Lemos JA, Blazing MA, Wiviott SD, Brady WE, White HD, Fox KA, et al. Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin and an early conservative initial management strategy: results from the A phase of the A-to-Z trial. Eur Heart J, 2004. 25(19):1688–94. doi: 10.1016/j.ehj.2004.06.028
9. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AMJr, Kastelein JJ, et al. JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med, 2008. 359(21):2195–207. doi: 10.1056/ NEJMoa0807646
10. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet, 2010. 375:735–42. doi: 10.1016/S0140-6736(09)61965-6
11. Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA, 2011. 305:2556–64. doi: 10.1001/jama.2011.860
12. Carter AA, Gomes T, Camacho X, Juurlink DN, Shah BR, Mamdani MM. Risk of incident diabetes among patients treated with statins: population-based study. BMJ, 2013. 346:f2610. doi: 10.1136/bmj.f2610
13. Thakker D, Nair S, Pagada A, Zamdade V, Malik A. Statin use and the risk of developing diabetes: a network meta-analysis. Pharmacoepidemiol Drug Saf, 2016. 25:1131–49. doi: 10.1002/pds.4020
14. Sattar NA, Ginsberg H, Ray K, Chapman MJ, Arca M, Averna M, et al. The use of statins in people at risk of developing diabetes mellitus: evidence and guidance for clinical practice. Atheroscler, 2014. Suppl:15(1):1–15. doi: 10.1016/j.atherosclerosissup.2014.04.001
15. Zhou Y, Yuan Y, Cai R-R, Huang Y, Xia W-O, Yang Y, et al. Statin therapy on glycaemic control in type 2 diabetes: a meta-analysis. Expert Opin Pharmacother, 2013. 14(12):1575–84. doi: 10.1517/14656566.2013.810210
16. Cui JY, Zhou RR, Han S, Wang TS, Wang LQ, Xie XH. Statin therapy on glycemic control in type 2 diabetic patients: a network meta-analysis. J Clin Pharm Ther, 2018. 43(4):556–70. doi: 10.1111/jcpt.12690
17. Erqou S, Lee CC, Adler AI. Statins and glycaemic control in individuals with diabetes: a systematic review and meta-analysis. Diabetologia, 2014. 57(12):2444–52. doi: 10.1007/s00125-014-3374-x
18. Alvarez-Jimenez L,Morales-Palomo F,Moreno-Cabañas A,Ortega JF, Mora-Rodrı́guez R. Effects of statin therapy on glycemic control and insulin resistance: A systematic review and meta-analysis. Eur J Pharmacol, 2023. 947:175672. doi: 10.1016/j.ejphar.2023.175672
19. Mansi IA, Chansard M, Lingvay I, Zhang S, Halm EA, Alvarez CA. Association of statin therapy initiation with diabetes progression: a retrospective matched-cohort study. JAMA Intern Med, 2022. 181:1–14. doi: 10.1001/jamainternmed.2021.5714
20. Zaharan NL, Williams D, Bennett K. Statins and risk of treated incident diabetes in a primary care population. Br J Clin Pharmacol, 2013. 75:1118–24. doi: 10.1111/j.1365-2125.2012.04403.x
21. Culver AL, Ockene IS, Balasubramanian R, Olendzki BC, Sepavich DM, Wactawski-Wende J, et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women’s Health Initiative. Arch Intern Med, 2012. 172:144–52. doi:10.1001/archinternmed.2011.625
22. Djoussé L, Song RJ, Cho K, Gaziano JM, Gagn DR. Association of statin therapy with incidence of type 2 diabetes among US Veterans. J Clin Cardiol Cardiovasc Ther, 2019. 1(1). doi: 10.31546/JCCCVT.1002
23. Cederberg H, Stančáková A, Yaluri N, Modi S, Kuusisto J, Laakso M. Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6-year follow-up study of the METSIM cohort. Diabetologia, 2015. 58:1109–17. doi: 10.1007/s00125-015-3528-5
24. Laakso M, Kuusisto J, Stančáková A, Kuulasmaa T, Pajukanta P, Lusis AJ, et al. The Metabolic Syndrome in Men study: a resource for studies of metabolic and cardiovascular diseases. J Lipid Res, 2017. 58(3):481–93. doi: 10.1194/jlr.O072629
25. Ahmadizar F, Ochoa-Rosales C, Glisic M, Franco OH, Muka T, Stricker BH. Associations of statin use with glycaemic traits and incident type 2 diabetes. Br J Clin Pharmacol, 2019. 85:993–1002. doi: 10.1111/bcp.13898
26. Crandall JP, Mather K, Rajpathak SN, Goldberg RB, Watson K, Foo S, et al. Statin use and risk of developing diabetes: results from the Diabetes Prevention Program. BMJ Open Diabetes Res Care, 2017. 5(1):e000438. doi: 10.1136/bmjdrc-2017-000438
27. Engeda JC, Stackhouse A, White M, Rosamond WD, Lhachimi SK, Lund JL, et al. Evidence of heterogeneity in statin-associated type 2 diabetes mellitus risk: A metaanalysis of randomized controlled trials and observational studies. Diabetes Res Clin Pract, 2019. 151:96–105. doi: 10.1016/j.diabres.2019.04.005
28. Abbasi F, Lamendola C, Harris CS, Harris V, Tsai M-S, Tripathi P, Abbas F, Reaven GM, Reaven PD, Snyder MP, et al. Statins are associated with increased insulin resistance and secretion. Arterioscler Thromb Vasc Biol. 2021;41:2786–2797. doi: 10.1161/ATVBAHA.121.316159
29. Baker WL, Talati R, White CM, Coleman CI. Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis. Diabetes Res Clin Pract, 2010. 87:98–107. doi: 10.1016/j.diabres.2009.10.008
30. Olotu BS, Shepherd MD, Novak S, Lawson KA, Wilson JP, Richards KM, Rasu RS. Use of Statins and the Risk of Incident Diabetes:A Retrospective Cohort Study. Am J Cardiovasc Drugs. 2016; 16:377–390. doi: 10.1007/s40256-016-0176-1
31. Cederberg H, Laakso M. Variable effects of statins on glucose homeostasis parameters and their diabetogenic role. Reply to Kostapanos MS, Agouridis AP and Elisaf MS [letter]. Diabetologia. 2015;58:1962–1963. doi: 10.1007/s00125-015-3674-9
32. Koh KK, Quon MJ, Han SH, Lee Y, Kim SJ, Shin EK. Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients. J Am Coll Cardiol. 2010;55:1209–1216. doi: 10.1016/j.jacc.2009.10.053
33. Puurunen J, Piltonen T, Puukka K, Ruokonen A, Savolainen MJ, Bloigu R, Morin-Papunen L, Tapanainen JS. Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2013;98:4798–4807. doi: 10.1210/jc.2013-2674
34. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet, 2010. 376:1670–81. doi: 10.1016/ S0140-6736(10)61350-5
35. Nielsen SF, Nordestgaard BG. Statin use before diabetes diagnosis and risk of microvascular disease: a nationwide nested matched study. Lancet Diabetes Endocrinol, 2014. 2(11):894–900. doi: 10.1016/S2213-8587(14)70173-1
36. Aygun, S.; Tokgozoglu, L. Comparison of Current International Guidelines for the Management of Dyslipidemia. J. Clin. Med. 2022, 11, 7249. https://doi.org/10.3390/ jcm11237249
Facebook 
Masuk dengan Email
